Loading…
Amgen Inc. is projected to rise to $454.85 by 2027, a +35% move from its current price of $336.06. AMGN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $332.08 | $336.16 | $340.29 | +0.03% |
| May 30 | $330.51 | $336.26 | $342.11 | +0.06% |
| May 31 | $329.32 | $336.36 | $343.54 | +0.09% |
| Jun 1 | $328.35 | $336.46 | $344.77 | +0.12% |
| Jun 2 | $327.50 | $336.56 | $345.87 | +0.15% |
| Jun 3 | $326.74 | $336.66 | $346.87 | +0.18% |
| Jun 4 | $326.06 | $336.76 | $347.80 | +0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $326.06 | $336.76 | $347.80 | +0.21% |
| Week 2 | $322.39 | $337.45 | $353.22 | +0.41% |
| Week 3 | $319.76 | $338.15 | $357.60 | +0.62% |
| Week 4 | $317.67 | $338.85 | $361.45 | +0.83% |
| Week 5 | $315.91 | $339.56 | $364.97 | +1.04% |
| Week 6 | $314.39 | $340.26 | $368.26 | +1.25% |
| Week 7 | $313.05 | $340.96 | $371.37 | +1.46% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Amgen Inc. is a healthcare company that discovers, develops, manufactures, and delivers human therapeutics worldwide. Its principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors.
The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd.
for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Amgen Inc. (AMGN) is a healthcare company with a broad portfolio of human therapeutics. It is currently priced at $339.30 and has a market capitalization of $183.12B, ranking 76 by market size.
The stock trades within a 30-day range of $311.83 to $369.19, reflecting moderate volatility and investor attention. The forecasted path for the asset shows a mix of near-term stability and long-term upside, with a 2026 average price of $339.30 and a potential range up to $461.96, indicating a neutral near-term stance but a bullish longer-term trajectory.
A major floor 8.7% below — a decisive break under it would weaken the trend.
The nearest floor, 3.6% below — buyers have tended to step in here.
The nearest ceiling, 5.7% above — a clean break opens room to run.
A major ceiling 15.5% above — clearing it would confirm fresh momentum.
Key AMGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AMGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $336.06 | Buy | $335.53 | Buy |
| MA 10 | $333.44 | Buy | $334.50 | Buy |
| MA 20 | $332.99 | Buy | $335.50 | Buy |
| MA 50 | $342.65 | Sell | $341.57 | Sell |
| MA 100 | $350.14 | Sell | $341.81 | Sell |
| MA 200 | $327.71 | Buy | $332.21 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.89 | Neutral |
| Stoch RSI (14) | 79.47 | Neutral |
| CCI (20) | 45.45 | Neutral |
| Williams %R (14) | -21.73 | Info |
| MACD (12,26,9) | 1.44 | Buy |
| ROC (12) | 1.31 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 78.27 | Neutral |
| TRIX (15) | -0.17 | Sell |
| Awesome (5,34) | -3.17 | Sell |
| Ultimate (7,14,28) | 64.48 | Neutral |
| Momentum (10) | -0.23 | Sell |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 339.29 | Sell |
| ADX (14) | 13.10 | Neutral |
| ATR (14) | 3.61 | Info |
The 30-day technical picture points to a balanced near-term outlook. RSI(14) is 50, suggesting neither overbought nor oversold momentum. The stock trades above the SMA200 at $327.22 but below the SMA50 at $343.86, hinting at a cautious upward bias. Support is listed at $323.85 and resistance at $355.30, framing a near-term zone of price activity.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $320.72 | $336.06 | $453.03 | 0% | Neutral | |
| $371.58 | $454.85 | $582.80 | +35% | Bullish | |
| $375.21 | $467.68 | $614.89 | +39% | Bullish | |
| $399.59 | $505.60 | $678.59 | +50% | Bullish | |
| $434.33 | $556.89 | $760.65 | +66% | Bullish | |
| $449.99 | $583.93 | $810.01 | +74% | Bullish | |
| $532.49 | $698.73 | $982.88 | +108% | Bullish | |
| $596.40 | $790.78 | $1,126.61 | +135% | Bullish | |
| $624.17 | $835.77 | $1,204.81 | +149% | Bullish | |
| $666.40 | $900.72 | $1,312.79 | +168% | Bullish | |
| $949.62 | $1,338.48 | $2,043.74 | +298% | Bullish | |
| $1,642.91 | $2,483.12 | $4,063.05 | +639% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $320.72 | $336.06 | $394.85 | +0.00% |
| June 2026 | $297.64 | $347.21 | $412.90 | +3.32% |
| July 2026 | $294.26 | $345.25 | $414.44 | -0.57% |
| August 2026 | $291.68 | $343.76 | $415.66 | -0.43% |
| September 2026 | $298.66 | $353.30 | $429.74 | +2.78% |
| October 2026 | $303.22 | $359.92 | $440.15 | +1.87% |
| November 2026 | $301.57 | $359.03 | $441.13 | -0.25% |
| December 2026 | $307.45 | $367.08 | $453.03 | +2.24% |
Click any year to see its month-by-month AMGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, AMGN is projected to trade between $320.72 and $453.03, averaging $336.06 — a potential gain of 0% from today's $336.06. Price action looks broadly range-bound.
Amgen Inc.'s 2027 outlook centres on $454.85, within a $371.58 to $582.80 range. That is up +35% on the projected 2026 average. That marks a +35% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, AMGN could reach as high as $614.89, with a base case around $467.68 and support toward $375.21 — roughly +39% from $336.06. Momentum favours further upside here.
Expect AMGN to range from $399.59 to $678.59 through 2029. The $505.60 average target implies a +50% move from current prices. That is up +8% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The AMGN price prediction for 2030 points to an average of $556.89 (low $434.33, high $760.65) — a potential gain of +66% on today's $336.06. Momentum favours further upside here.
In 2031, AMGN is projected to trade between $449.99 and $810.01, averaging $583.93 — a potential gain of +74% from today's $336.06. That is up +5% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Amgen Inc.'s 2032 outlook centres on $698.73, within a $532.49 to $982.88 range. That is up +20% on the projected 2031 average. That marks a +108% change versus current levels. Momentum favours further upside here.
By 2033, AMGN could reach as high as $1,126.61, with a base case around $790.78 and support toward $596.40 — roughly +135% from $336.06. Buyers look set to stay in control over this stretch.
Expect AMGN to range from $624.17 to $1,204.81 through 2034. The $835.77 average target implies a +149% move from current prices. That is up +6% on the projected 2033 average. Momentum favours further upside here.
The AMGN price prediction for 2035 points to an average of $900.72 (low $666.40, high $1,312.79) — a potential gain of +168% on today's $336.06. Buyers look set to stay in control over this stretch.
In 2040, AMGN is projected to trade between $949.62 and $2,043.74, averaging $1,338.48 — a potential gain of +298% from today's $336.06. That is up +49% on the projected 2035 average. Momentum favours further upside here.
Amgen Inc.'s 2050 outlook centres on $2,483.12, within a $1,642.91 to $4,063.05 range. That is up +86% on the projected 2040 average. That marks a +639% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in AMGN today (≈ 2.975659 AMGN) could be worth
$7,388.91
+$6,388.91 (+639%) by 2050 · US Dollar
Based on the average projected AMGN price of $2,483.12 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AMGNwould be worth at today's price.
$1,000 invested in AMGN on May 27, 2025 (≈ 3.578458 AMGN) would be worth
$1,202.58
+$202.58 (+20.3%) today · 1.20× · US Dollar
Based on a AMGN entry price of $279.45 vs. today's $336.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $331.57 | $1,013.54 | +1.4% |
| 1 month ago | $340.18 | $987.89 | -1.2% |
| 3 months ago | $379.33 | $885.93 | -11.4% |
| 6 months ago | $345.46 | $972.79 | -2.7% |
| 1 year ago | $279.45 | $1,202.58 | +20.3% |
| All time (5.0y) ago | $233.58 | $1,438.74 | +43.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AMGN forecast.
Our base-case forecast reaches $670.00 around 2032.
Implied market cap at $670.00: $361.6B
The multi-year forecast shows a bullish trajectory with rising averages and expanding upside. For 2026 the avg is $339.30 with a min of $320.72 and a max of $461.96, implying a neutral stance in the near term. From 2027 onward, the outlook becomes consistently bullish, with 2027 avg $462.06 and 2030 avg $571.07, and max values climbing to $780.18.
The forecast extends to 2050 with an average of $2,612.94 and a max of $4,275.82, yielding an overall ROI of 670.1% by 2050. Key intermediate milestones include 2040 avg $1,385.58 and 2032-2035 periods showing accelerating gains, supported by bullish sentiment through the horizon. Investors should acknowledge that these are estimates and not guarantees, with inherent uncertainty and potential downside risks.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $571.07, a min of $445.31, and a max of $780.18, with an ROI of 68.3% and bullish sentiment.
The long-term forecast is bullish from 2027 onward, with 2027 avg $462.06 and 2030 avg $571.07, and 2050 avg $2,612.94 with an ROI of 670.1% in 2050, though these are estimates and not guarantees.
Yes—the 2030 max is $780.18.
Current price is $339.30 and market cap is $183.12B.
RSI(14) is 50. SMA50 is $343.86. SMA200 is $327.22. Support is at $323.85 and resistance at $355.30. The 30-day range is $311.83 to $369.19, and annualized volatility is 20%.
Amgen Inc. Community Discussion
0Share your Amgen Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.